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Interleukin-2 (IL-2) is a pleiotropic cytokine produced after antigen activation that plays pivotal roles in the
immune response. Discovered as a T cell growth factor, IL-2 additionally promotes CD8+ T cell and natural
killer cell cytolytic activity and modulates T cell differentiation programs in response to antigen, promoting
naı¨ve CD4+ T cell differentiation into T helper 1 (Th1) and T helper 2 (Th2) cells while inhibiting T helper 17
(Th17) and T follicular helper (Tfh) cell differentiation. Moreover, IL-2 is essential for the development and
maintenance of T regulatory cells and for activation-induced cell death, thereby mediating tolerance and
limiting inappropriate immune reactions. In this review, we focus on the molecular mechanisms and complex
cellular actions of IL-2, its cooperative and opposing effects with other cytokines, and how both promoting
and blocking the actions of IL-2 are being utilized in clinical medicine.Introduction
Interleukin-2 (IL-2) was first discovered over 35 years ago as an
activity present in supernatants of activated human T cells that
mediates T cell growth and proliferation (Morgan et al., 1976;
previously reviewed in Boyman and Sprent, 2012; Kim et al.,
2006; Lin and Leonard, 2000; Malek and Castro, 2010). This
four a-helix bundle type 1 cytokine (Bazan, 1990) was the first
type 1 cytokine cloned (Taniguchi et al., 1983) and the first
type 1 cytokine for which a receptor component was cloned
(Leonard et al., 1984; Nikaido et al., 1984) and has served as
a paradigm for other cytokines, particularly because it is one of
two cytokines to share the IL-2 receptor b chain (IL-2Rb) and
one of six cytokines to share the common cytokine receptor g
chain, gc (Figure 1), with both of IL-2Rb and gc having been
discovered as components of the IL-2 receptor (Leonard, 2001).
Besides its potent T cell growth factor activity, IL-2 induces
proliferation of natural killer (NK) cells and augments their cyto-
lytic activity as well as that of lymphokine-activated killer cells
(Siegel et al., 1987), promotes antibody production and pro-
liferation by B cells (Mingari et al., 1984), and is essential for
activation-induced cell death (AICD), which is important for
homeostasis and the elimination of potentially harmful autoreac-
tive cells, at least in part by a Fas and FasL-dependent mecha-
nism (Lenardo et al., 1999). IL-2 also drives the development
of CD4+FOXP3+ regulatory T cells (Treg cells) (Malek and Castro,
2010), which have suppressor function and mediate tolerance
(Littman and Rudensky, 2010; Sakaguchi et al., 2008; Shevach,
2009). More recently, the range of recognized actions of IL-2
has expanded, with roles in promoting the differentiation of T
helper 1 (Th1) (Liao et al., 2011; Shi et al., 2008) and Th2 cells
(Cote-Sierra et al., 2004; Liao et al., 2008), while inhibiting Th17
(Laurence et al., 2007) and T follicular helper (Tfh) cell (Balles-
teros-Tato et al., 2012) development, but nevertheless pro-
moting Th17 cell expansion once cells develop (Amadi-Obi
et al., 2007). IL-2 also is critical for production of IL-9 (Schmitt
et al., 1994). Thus, IL-2 has broad essential biological actions,
not only driving T cell proliferation and modulating effector celldifferentiation, but also limiting potentially dangerous autoim-
mune reactions. Herein, we discuss the molecular and cellular
biology of IL-2, its signaling mechanism, and its actions, as
well as its relationship with the five other cytokines (IL-4, IL-7,
IL-9, IL-15, and IL-21) that share components of the IL-2
receptor. Finally, we discuss the use of IL-2 as a therapeutic
agent and the utility of blocking the action of IL-2 and related
cytokines using Janus kinase (JAK) inhibitors, an exciting new
class of immunosuppressive drugs.
IL-2
IL-2 is a 15.5 kDa type 1 four a-helical bundle cytokine produced
primarily by CD4+ T cells following antigen stimulation (Leonard,
2001) but also produced to a lesser extent by CD8+ cells (Paliard
et al., 1988), NK T cells (Yui et al., 2004), activated dendritic cells
(DCs) (Granucci et al., 2001), and mast cells (Hershko et al.,
2011). In T cells, induction of IL-2 transcription requires two
signals, mediated by calcium and protein kinase C. IL-2 tran-
scription ismediated bymultiple transcription factors (Figure 2A),
including nuclear factor of activated T cells (NFAT) family pro-
teins (Mu¨ller and Rao, 2010), activator protein-1 (AP-1, FOS-
JUN family dimers), nuclear factor k-light-chain-enhancer of
activated B cells (NF-kB), and the octamer transcription factor,
OCT-1 (Kim et al., 2006). Of five NFAT proteins (NFATC1,
NFATC2, NFATC3, NFATC4, and NFAT5), all but NFAT5 are
expressed in the cytosol, with NFATC1 and NFATC2 highly ex-
pressed in lymphocytes (Mu¨ller andRao, 2010), andmice lacking
both of these proteins express essentially no T cell receptor
(TCR)-induced IL-2 (Peng et al., 2001). NFAT translocation to
the nucleus is blocked by cyclosporine A and FK-506 (Flanagan
et al., 1991). TCR engagement activates AP-1, which with NFAT,
binds to composite sites in the IL-2 promoter (Figure 2A) (Mu¨ller
and Rao, 2010). In anergic cells, the distal AP-1 site binds the
transcription factors CREB and/or CREM instead of AP-1;
CREB activates expression of the transcription factors cJUN,
cFOS, FRA2, and FOSB, and a dominant-negative CREB greatly
decreases TCR-induced IL-2 expression (Kim et al., 2006).Immunity 38, January 24, 2013 ª2013 Elsevier Inc. 13
Figure 1. The gc Family of Cytokines
Shown are the receptors for IL-2, IL-4, IL-7, IL-9,
IL-15, and IL-21, as well as major actions for these
cytokines. Crosses in red indicate that mutation of
IL2RG gene, which encodes gc, results in X-linked
severe combined immunodeficiency in humans
(XSCID, where both T cells and NK cells are
greatly diminished [T–B+NK– SCID]), mutation of
IL2RA results in an autoimmune syndrome,
defective expression of IL2RB results in NK-defi-
cient SCID (where T and B cells remain [T+B+NK–
SCID]), and mutation of IL7R causes T cell selec-
tive form of SCID, where B and NK cell numbers
are normal (T–B+NK+ SCID). JAK3 is not shown as
it interacts with the cytoplasmic domain of gc;
however, mutations in JAK3, as noted in the text,
cause a T–B+NK– for SCID, like XSCID.
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ReviewFOXP2 also cooperates with NFAT to drive IL-2 expression,
whereas FOXP3 can replace FOXP2 to inhibit IL-2 expression
while inducing the Treg cell markers IL-2Ra and CTLA4 (Wu
et al., 2006). NF-kB binds to two sites in the IL-2 promoter,
including one in the CD28 response element, and expression
of IL-2 is elevated inNfkb1/mice (Kim et al., 2006), supporting
the model that p50 homodimers repress IL-2 expression,
whereas complexes containing p65 or c-Rel activate its expres-
sion. Oct1 andOct2 bind to octamer binding sites and cooperate
with AP-1 for IL-2 gene induction by phorbol myristate acetate
(PMA) + ionomycin; The transcription factors SP1, Egr1, and
GABP also act as positive regulators (Kim et al., 2006).
TRIM28, a component of heterochromatin, is phosphorylated
after TCR stimulation and promotes IL-2 expression, with dimin-
ished IL-2 production in mice in which the Trim28 gene was
conditionally deleted as well as in Trim28 small interfering
RNA-treated human Jurkat T cells (Chikuma et al., 2012).
IL-2 transcription also is negatively regulated. NIL2A (TCF-8) is
encoded by ZEB1, a zinc finger E box binding protein that
binds 105 bp 50 of the transcription start site and suppresses
transcription (Williams et al., 1991). Prior to activation, the
T-lineage factor SATB1 binds to the human IL-2 promoter and
in a phosphorylation-dependent manner recruits histone deace-
tylase-1 (HDAC1) and silences Il2 expression, whereas after
HIV-1 infection, binding of HIV Tat as well as CBP and/or p300
to HDAC1 induces IL-2 (Pavan Kumar et al., 2006). BLIMP-1
and Aiolos (encoded by Prdm1 and Ikzf3, respectively) also
repress IL-2 expression. IL-2 induces BLIMP-1, which binds
IL-2 and cFos promoter regions and inhibits their expression
(Martins et al., 2008). In Th17 cells, Aiolos is induced in a signal
transducer and activator of transcription-3 (STAT3)-dependent
and aryl hydrocarbon receptor (Ahr)-dependent fashion and
binds a CCTCCCATGC motif in the Il2 promoter in Th17 but14 Immunity 38, January 24, 2013 ª2013 Elsevier Inc.not Th1 or Th0 cells, suppressing Il2
expression in Th17 cells (Quintana
et al., 2012). Interestingly, microRNAs
(miRNAs) also play a role in regulation of
IL-2 expression. For example, miR146a,
which is induced by TCR stimulation in
primary T cells, can impair AP-1 produc-
tion and IL-2 expression (Curtale et al.,
2010), whereas miR9 induced by TCR
stimulation enhances IL-2 expression, atleast in part, by suppressing PRDM1 expression (Thiele et al.,
2012), and miR184 represses expression of IL-2 in umbilical
cord CD4+ T cells (Weitzel et al., 2009). Thus, IL-2 production
is both positively and negatively regulated.
Three Classes of IL-2 Receptors
IL-2 signals via specific receptors (Robb et al., 1981), with three
classes of cell surface receptors formed by various combina-
tions of three IL-2R subunits (Figure 3), IL-2Ra, IL-2Rb, and
IL-2Rg (Kim et al., 2006; Lin and Leonard, 2000; Malek and
Castro, 2010). IL-2Ra (CD25) was originally called Tac antigen
based on the demonstration that anti-Tac monoclonal antibody
(mAb) (Uchiyama et al., 1981) blocked the binding of IL-2
(Leonard et al., 1982). IL-2Rb (CD122) (Sharon et al., 1986; Teshi-
gawara et al., 1987; Tsudo et al., 1986) is also part of the IL-15R
complex (Giri et al., 1994), and IL-2Rg (CD132) (Takeshita et al.,
1992) was renamed as the common cytokine receptor g chain, gc
(Leonard et al., 1995; Noguchi et al., 1993a; Russell et al., 1993);
gc is now known to be shared by IL-2, IL-4, IL-7, IL-9, IL-15, and
IL-21 (Leonard, 2001; Rochman et al., 2009).
IL-2Ra is absent or minimally expressed on resting T and NK
cells, but its transcription is potently inducedonTcells stimulated
via the TCR or IL-2 (Depper et al., 1984, 1985; Leonard et al.,
1985) or on NK cells stimulated with IL-2 (Siegel et al., 1987);
the expression level of the IL-2Rb chain is low on T cells but is
induced by certain stimuli, including IL-2 (Siegel et al., 1987); gc
is also expressed on these cells but is less inducible than IL-
2Ra or IL-2Rb (Cao et al., 1993). IL-2Ra is the ‘‘low-affinity’’
IL-2 receptor (Kd108 M); IL-2Rb binds poorly (Kd1 mM) by it-
self, but the combination of IL-2Rb with gc forms the interme-
diate-affinity IL-2 receptor (Kd 109 M); and all three subunits
together form the high-affinity IL-2 receptor (Kd1011M) (Take-
shita et al., 1992), the structure for which has been solved
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Figure 2. Factors Regulating the IL2, IL2RA,
IL2RB, and IL2RG Genes
For each gene, the binding locations of tran-
scription factors are shown. For some of these
factors, there are only in vitro data that indicate
their importance, whereas for others such as
STAT5A and STAT5B, extensive in vivo data have
established their importance (e.g., of STAT5A and
STAT5B for regulation of IL-2Ra expression [Na-
kajima et al., 1997; Imada et al., 1998]).
(A) Multiple factors, including for example NFAT,
AP1, andNF-kB, bind to and regulate the IL2 gene.
(B) In the IL2RA gene, PRRI binds SP1, SRF, and
NF-kB; PRRII binds Elf-1, as well as HMG-I and/or
HMG-Y; PRRIII bindsSTAT5A,STAT5B, ELF1, and
GABP, as well as HMG-I and/or HMG-Y; PRRIV
binds NFAT, AP1, STAT5A, and STAT5B; PRRV
binds SMAD3, AP1, and CREB-ATF factors; and
PRRVI binds AP1 and CREB-ATF factors.
(C) Factors including ETS1 bind to and regulate
the IL2RB gene.
(D) Only limited information is available regarding
the factors regulating IL2RG.
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Review(Stauber et al., 2006; Wang et al., 2005). High affinity IL-2 binding
results from IL-20s rapid on and off rates to IL-2Ra coupled to
slower on and off rates to intermediate affinity receptors (Lowen-
thal and Greene, 1987; Wang and Smith, 1987). When IL-2Ra
and IL-2Rb are coexpressed without gc, ‘‘pseudo-high affinity’’
binding (Kd 1010 M) (Arima et al., 1992) is achieved but no
signaling occurs. The intermediate and high affinity receptors
are functional, corresponding to the requirement for heterodi-
merization of IL-2Rb and gc cytoplasmic domains for signaling
(Nakamura et al., 1994; Nelson et al., 1994). Intermediate affinity
receptors are present on resting T (Zhang et al., 1998) and NK
cells (Siegel et al., 1987), whereas high-affinity receptors are ex-
pressed by activated lymphocytes (Robb et al., 1981). Binding of
IL-2 to intermediate affinity receptors induces cell growth and
cytolytic activity (Siegel et al., 1987) and IL-2Ra transcription
(Depper et al., 1985). After T cell activation, IL-2Ra is rapidly
induced and high-affinity receptors form, increasing responsive-
ness to IL-2. Although IL-2 primarily acts as a soluble factor via
intermediate and high-affinity receptors, like IL-15, IL-2 can be
presented in trans, where IL-2 bound to IL-2Ra on one cell stim-
ulates another cell that expresses IL-2Rb and gc (Wuest et al.,
2011) (Figure 3). However, unlike the relatively high-affinity
binding of IL-15 to IL-15Ra (Waldmann, 2006), IL-2 binds with
relatively low affinity to IL-2Ra with rapid on and off rates, as
noted above. Accordingly, cis-based IL-2 signaling is likely
favored whenever a cell expresses all three chains, and trans
signaling presumably requires relatively high local concentra-
tions of IL-2. In addition to cell surface IL-2Ra, IL-2Ra can exist
in a soluble form (sIL-2Ra) that can be released from the cell
surface (Figure 3), including in infectious disorders, transplanta-
tion rejection, and autoimmune inflammatory states, with an
elevated amount of sIL-2Ra being detected in certain hemato-
logic malignancies. In some diseases, the concentration ofImmunity 38sIL-2Ra correlates with disease activity
and prognosis (Rubin and Nelson, 1990).
Interestingly, IL-2Ra is expressed on
a fraction of CD4–CD8– thymocytes (God-
frey et al., 1993), but such IL-2Ra expres-sionmay reflect the activation state or ability to trans-present IL-2
rather than responsiveness to IL-2. IL-2Ra is also expressed by
DC populations (Driesen et al., 2008), including after CpG or
CD40 ligand stimulation of human plasmacytoid DCs (Naranjo-
Go´mez et al., 2007). Both cell surface and soluble IL-2Ra are ex-
pressed by primary BDCA-1+myeloid DCs stimulatedwith tumor
necrosis factor a (TNF-a) and prostaglandin E2, as well as on
tumor-associated DCs. These cells might sequester IL-2 and
diminish T cell proliferation, thus contributing to immunosuppres-
sion by DCs (von Bergwelt-Baildon et al., 2006), but IL-2Ra-ex-
pressing DCs can also trans-present IL-2, with agonistic effects,
consistent with inhibition of T cell activation by antigen-specific
DCs and diminished brain inflammation in multiple sclerosis
patients treated with daclizumab, a humanized antibody to IL-
2Ra (Wuest et al., 2011).
Regulation of IL-2 Receptor Expression
The three IL-2R chains are independently regulated. IL-2Ra is
transcriptionally induced by stimulation via the T cell receptor
(Leonard et al., 1985), by cytokines including IL-1, IL-2, IL-7,
IL-12, IL-15, TNF-a, and transforming growth factor-b (TGF-b),
by transactivator proteins Tax of human T cell leukemia virus-
1 (HTLV-1) and TaxII of HTLV-2, and by activators of protein
kinase C (Kim et al., 2006). Of six positive regulatory regions
(PRRI, PRRII, PRRIII, PRRIV, PRRV, and PRRVI) in the IL-2Ra
gene (Figure 2B) (Kim et al., 2006), all but PRRIII contribute to
antigen and mitogenic stimulation. PRRIII, PRRIV, and addi-
tional regions of the IL-2Ra gene based on chromatin immuno-
precipitation sequencing (ChIP-Seq) data (Lin et al., 2012) are
IL-2-response elements that contain interferon-g (IFN-g) activa-
tion sequence (GAS) motifs and bind STAT5 proteins. Corre-
spondingly, IL-2-induced IL-2Ra expression is diminished in
Stat5a/ and Stat5b/ mice (Imada et al., 1998; Nakajima, January 24, 2013 ª2013 Elsevier Inc. 15
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Transpresentation Figure 3. Classes of IL-2 Receptors
Shown are the three classes of IL-2 recep-
tors (high-affinity, intermediate affinity, and low
affinity), with receptor composition, Kd’s, receptor
composition, and associated JAK kinases. Also
shown is trans-presentation of IL-2 by a DC that
expresses IL-2Ra to a T cell that expresses IL-2Rb
and gc. On the right is the soluble IL-2 receptor
(soluble IL-2Ra) with bound IL-2. As discussed in
the text, IL-2 is produced primarily by activated
CD4+ T cells.
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gene is dependent on STAT proteins, its induction by TCR,
TNF-a, and Tax proteins of HTLV-1 or HTLV-2, requires
NF-kB binding (Kim et al., 2006) (Figure 2B). NFAT sites are
also present, consistent with diminished IL-2Ra expression in
Nfatc2/ mice (Schuh et al., 1998). TGF-b cooperates with
TCR signaling to act via PRRV, which has a SMAD (‘‘small
mothers against decapentaplegic’’) binding site (Kim et al.,
2005). Like the Il2 gene, SATB1 (special AT-rich sequencing-
binding protein-1) binds to and suppresses the Il2ra gene,
with elevated Il2ra expression in Satb1/ double- positive
(DP) thymocytes (Alvarez et al., 2000). Two negative regulatory
elements, NRE-1 and NRE-2, are also present in the gene (Kim
et al., 2006).
IL-2Rb is expressed bymultiple lymphohematopoietic popula-
tions of cells, including NK cells, resting T cells, monocytes, and
neutrophils; on T cells, TCR stimulation, PMA, IL-2, and IL-4
each augments IL-2Rb expression via both transcriptional and
posttranscriptional regulation (Kim et al., 2006). The IL-2Rb
promoter binds the Ets family proteins, Ets1 and GABP, as well
as Egr1 and Sp1 (Lin et al., 1993; Lin and Leonard, 1997)
(Figure 2C), with decreased IL-2Rb expression in Ets1/ NK
cells (Ramirez et al., 2012). The Ewing sarcoma gene-Wilms
tumor suppressor (EWS-WT1) fusion transcription factor also
binds to and augments IL-2Rb expression (Wong et al., 2002).
Interestingly, there is a run of Z-DNA within this gene, but its
physiological significance is unknown (Kim et al., 2006). IL-2Rb
and IL-2Ra expression was reported on fibroblasts (Gruss
et al., 1996), but the significance of such expression also is
unclear.
Like IL-2Rb, IL-2Rg is constitutively expressed and mainly
restricted to lymphohematopoietic cells (Cao et al., 1993).
IL-2 and IFN-g are each shown to enhance and TGF-b1
to inhibit IL-2Rg expression in human monocytes (Bosco
et al., 1994), but little is still known about IL2RG regulation
(Figure 2D).16 Immunity 38, January 24, 2013 ª2013 Elsevier Inc.Signaling Via the IL-2 Receptor
After IL-2 engagement, the IL-2 receptor
complex is rapidly internalized, with
IL-2Ra located in early transferrin+ endo-
somes that recycle to the plasma mem-
brane, whereas IL-2Rb and gc are
targeted to Rab7+ vesicles that are sorted
toward degradation (He´mar et al., 1995).
Following receptor binding, IL-2 activates
multiple signaling pathways (Figure 4).
Heterodimerization of the IL-2Rb and gc
cytoplasmic domains leads to activation of Janus family tyrosine
kinases, JAK1 and JAK3, with JAK1 associating with IL-2Rb and
JAK3 with gc (Boussiotis et al., 1994; Miyazaki et al., 1994;
Russell et al., 1994). The JAK kinases activate each other and
phosphorylate key residues in IL-2Rb. Phosphorylation of Y338
in humans (Y341 in mice) allows association of the SHC adaptor
protein (Friedmann et al., 1996), which provides a platform for
Ras-MAP kinase activation and promotes cell growth. Phos-
phorylation of Y392 and Y510 in humans (Y395 and Y498 in
mice) mediates recruitment of STAT1, STAT3, STAT5A, and
STAT5B, with most potent and sustained activation of STAT5
proteins (Friedmann et al., 1996; Lin et al., 2012). IL-2 also acti-
vates the phosphoinositol 3-kinase (PI 3-kinase)-Akt-p70 S6
kinase signaling pathway (Lin and Leonard, 2000; Malek and
Castro, 2010), which promotes cell growth and survival (Franke
et al., 1997). This pathway is inhibited by rapamycin, which
blocks the function of a serine and threonine kinase, mTOR
(mechanistic target of rapamycin), which is activated by PI-3K-
AKT pathway (Thomson et al., 2009). STAT5A and STAT5B
dock on IL-2Rb, are phosphorylated, dimerize, and translocate
to the nucleus, where they bind to target genes essential for
effector cell function and T cell growth (Friedmann et al., 1996;
Lin et al., 2012), as well as differentiation (Liao et al., 2008,
2011). Generally, IL-2 is viewed as an activator, inducing more
genes than it represses (Lin et al., 2012). Interestingly, a miRNA,
miR-182, that is induced by IL-2 is an inhibitor of the transcription
factor FOXO1, which blocks cell-cycle progression in resting
T cells, thereby helping to mediate the clonal expansion of acti-
vated helper T cells (Stittrich et al., 2010).
In addition to their tyrosine phosphorylation-mediated dimer-
ization, like STAT1 and STAT4 (Chen et al., 2003), STAT5 pro-
teins can interact via their N-terminal region (N-domains),
allowing tetramer or higher order oligomer formation and binding
to tandemGASmotifs (Lin et al., 2012). The importance of STAT5
tetramers has been analyzed by generating mice in which Il28
and Phe81 in the STAT5 N-domain have been mutated to
Figure 4. Schematic of Major IL-2 Signaling
Pathways
Shown is the activation of PI 3-K-AKT, JAK-STAT,
and SHC-RAS-MAPK signaling pathways. Also
shown are potential therapeutic points of control
for IL-2 signaling, with anti-Tac (daclizumab),
rapamycin, and JAK1 or JAK3 inhibitors being
shown in red. The cartoon shows signaling by both
STATs dimers and tetramers. The figure indicates
that IL-2 activates more STAT5 than STAT3 and
more STAT3 than STAT1. ERK refers to both ERK1
and ERK2. MEK refers to both MEK1 and MEK2.
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genes (Lin et al., 2012), allowing formation of STAT5 dimers
but not tetramers. ChIP-Seq and gene expression analyses of
cells from wild-type and mutant mice has allowed the identifica-
tion of genes regulated by STAT5 dimers versus tetramers and
the definition of dimer versus tetramer consensus motifs (Lin
et al., 2012). Defective expression of certain genes, such as
Il2ra, in the tetramerization-defective mice, can readily be
attributed to known STAT5 tetramer binding sites, and these
mice have decreased NK cell and CD8+ T cells and defective
gene expression in response to IL-2 or IL-15. Moreover, these
animals exhibit diminished virus-specific CD8+ T cell expan-
sion, particularly early after infection with lymphocytic chorio-
meningitis virus (LCMV) or adenovirus 5, indicating that
STAT5 tetramers are more important for early responses than
for the later memory development and maintenance (Lin
et al., 2012). An adoptive-transfer colitis model reveals that
normal Treg cell-mediated suppression is also dependent on
STAT5 tetramers (Lin et al., 2012), consistent with their require-
ment for IL-2 signaling (Malek and Castro, 2010; Malek et al.,
2002). Thus, IL-2 function requires STAT5 tetramers as well
as dimers.
IL2RG, X-Linked Severe Combined Immunodeficiency,
and a Major Conundrum
Studies of the IL-2 receptor g chain have revealed that the
gene encoding this receptor protein, IL2RG, is located at the
disease locus for X-linked severe combined immunodeficiency
(XSCID) at Xq13 (Noguchi et al., 1993b). XSCID is a profound
inherited immunodeficiency affecting approximately 1 in every
200,000 live births in the United States, representing the most
common inherited immunodeficiency. XSCID is characterized
by essentially absent T and NK cells; B cell numbers are rela-
tively normal but are nonfunctional. Without successful boneImmunity 38marrow transplantation, affected individ-
uals typically die in the first year of life
(Cavazzana-Calvo et al., 2005; Leonard,
1996). Strikingly, IL2RG (encoding IL-
2Rg) is mutated in humans with XSCID
(Noguchi et al., 1993b). This finding was
most unexpected, given normal T and
NK cell development in humans with
IL-2 deficiency or in Il2/ mice, leading
to the hypothesis that IL-2Rg has roles
beyond IL-2 (Noguchi et al., 1993b).
Indeed, IL-2Rg was initially shown to bea critical component for the IL-4 and IL-7 receptors and subse-
quently for IL-9, IL-15, and IL-21 as well, hence its being re-
named as the common cytokine receptor g chain, gc (Leonard,
2001; Noguchi et al., 1993a) (Figure 1). The knowledge that
JAK3 physically associates with gc led to speculation and confir-
mation that mutations in JAK3 caused a similar clinical and
immunological disease to XSCID (Macchi et al., 1995; Russell
et al., 1995). The identification of IL7R-deficient SCID patients
with a selective T cell defect (Puel et al., 1998) indicates that
the T cell defect in XSCID results from defective IL-7 signaling;
the ability of IL-15 to drive NK development (Waldmann, 2006)
indicates that defective IL-15 signaling explains the lack of
NK cells (Leonard, 1996), and analysis of mice in which both
the Il21r and Il4 genes were deleted revealed that defective
signaling by the combination of IL-4 and IL-21 explained the
defective B cell function in XSCID (Ozaki et al., 2002). Thus,
although studies of IL-2 led to the discovery of the cause of
XSCID, defective IL-2 signaling is not responsible for the major
defects in that disease.
Consistent with the conclusion that defective IL-15 signaling is
responsible for the lack of NK cells in XSCID and JAK3 defi-
ciency, defective expression of IL-2Rb, which is shared by the
receptors for IL-2 and IL-15, results in an NK-deficient form of
SCID (Gilmour et al., 2001) (see Figure 1). Interestingly, mutation
of IL2RA results not in SCID but an autoimmune syndrome
(Sharfe et al., 1997) (see Figure 1), consistent with a selective
defect in IL-2 signaling, which is required for normal Treg cell
development (Malek and Castro, 2010). As expected, like
humans with IL2RB deficiency, Il2rb/ mice also lack NK cells,
and like humans with IL2RA deficiency, Il2ra/ mice exhibit an
autoimmune syndrome. Interestingly, Il2rg/mice have a major
defect not only in T and NK cells but also in B cells, given the
requirement for IL-7 for B cell development in mice but not
humans (Leonard, 2001). These animals do not exhibit, January 24, 2013 ª2013 Elsevier Inc. 17
Figure 5. IL-2 Is Important in Many Types of T Effector Cell
Differentiation
Shown is the induction by IL-2 of IL-12Rb2 to promote Th1 cell differentiation,
of IL-4Ra to promote Th2 cell differentiation, and of IL-2Ra to promote Treg cell
differentiation. Conversely, IL-2 represses expression of gp130 (and IL-6Ra)
while inducing T-bet (data not shown) to repress Th17 cell differentiation. IL-2
is also a repressor of Tfh differentiation based on its repression of BCL6
expression. Finally, IL-2 promotes the differentiation, expansion, and the
cytolytic activity of cytotoxic T cells.
Immunity
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and NK cells (Leonard, 2001).
IL-2 and IL-15 Are Two Closely Related but Biologically
Distinct Cytokines
As discussed above, IL-2 and IL-15 are highly related to each
other and both cytokines bind to receptors that contain IL-2Rb
and gc to transduce their signals, although they have distinct
a chains (Waldmann, 2006). Their three-dimensional quaternary
structures reveal that IL-15 binds to the IL-2Rb and gc hetero-
dimer in nearly identical fashion to that of IL-2, with similar
gene induction profiles (Ring et al., 2012), but yet they are very
distinctive biologically (Waldmann, 2006) (Figure 1), based in
part on distinctive patterns of expression for IL-2 and IL-15, as
well as IL-2Ra versus IL-15Ra. Despite the fact that both IL-2
and IL-15 share IL-2Rb and gc as receptor components and
activate common signaling pathways, they exhibit signaling
differences (Castro et al., 2011; Cornish et al., 2006). For
example, in freshly isolated CD8+ splenic T cells, IL-15 is more
potent than IL-2 in driving cell-cycle progression andmore effec-
tively cooperates with IL-21 than does IL-2 (Zeng et al., 2005),
whereas in antigen-activated CD8+ T cells, IL-2 more potently
increases protein synthesis and cell proliferation than does IL-
15 (Cornish et al., 2006). This effect of IL-2 correlates with rapid
expansion of short-lived effector cells, whereas IL-15 favors the
maintenance of long-lived, memory phenotype cells (Waldmann,
2006). As noted above, both cytokines can use trans-presenta-
tion although this mechanism is more utilized by IL-15.
Because of the sharing of IL-2Rb, a monoclonal antibody
(Mikb1) to this protein can inhibit not only IL-2 signaling but
also IL-15 signaling. Indeed, it was reported that abnormal
IL-15 responses might contribute to the survival and expansion
of certain leukemias and/or lymphomas, and moreover, Mikb1
blocked trans-presentation of IL-15 and now is being used in
a phase I clinical trial for T cell large granular lymphocytic
leukemia (T-LGL) (Waldmann et al., 2012).
IL-2 and Treg Cells
Treg cells play vital roles in preventing autoimmunity, limiting
inflammatory responses, and maintaining immune homeostasis
(Littman and Rudensky, 2010; Sakaguchi et al., 2008; Shevach,
2009). A hallmark of Treg cells is expression of the forkhead tran-
scription factor FOXP3, which is necessary but not sufficient for
Treg development (Figure 5). TCR-induced CpG hypomethyla-
tion of conserved noncoding DNA sequences (CNSs) critically
regulates FOXP3 expression and is important for establishing
Treg cell identity (Kim and Leonard, 2007; Ohkura et al., 2012;
Zheng et al., 2010). Most FOXP3+ Treg cells are CD4+CD25+
cells (Sakaguchi et al., 2008; Shevach, 2009). In addition to
thymic-derived natural Treg cells, naive peripheral CD4+ T cells
can become CD4+FOXP3+-inducible Treg cells when stimulated
with anti-CD3, TGF-b, and IL-2, with a critical role for IL-2 in their
generation and expansion (Davidson et al., 2007; Zheng et al.,
2007). The suppressive actions of Treg cells in part can be attrib-
uted to their ability to efficiently compete with effector CD4+
T cells for the available IL-2 (Busse et al., 2010; Pandiyan
et al., 2007). Interestingly, this can result in apoptosis of the
effector cells, in part through an increased expression of proap-
optotic protein BIM and a decreased phosphorylation of the18 Immunity 38, January 24, 2013 ª2013 Elsevier Inc.proapoptotic protein BAD due to lower AKT activity (Pandiyan
et al., 2007).
An essential role of IL-2 in controlling immune homeostasis
was first suggested by the spontaneous lethal autoimmunity
found in mice lacking expression of IL-2, IL-2Ra, or IL-2Rb (Leo-
nard, 2001). Adoptive transfer of wild-type CD4+CD25+ T cells
into Il2rb/micepreventsautoimmunity,demonstratingacritical
role for IL-2 for Treg cell development and function in vivo (Antony
et al., 2006; Malek and Castro, 2010; Malek et al., 2002). Consis-
tent with this, in the nonobese diabetic (NOD) mouse model of
type 1 diabetes, intraislet Treg cell dysfunction due to defective
IL-2 production results in the breakdown of self-tolerance, but
administering low doses of IL-2 and IL-2 mAbs (Boyman et al.,
2006), which form stable immune complexes, increased Treg
cell survival and decreased the incidence of diabetes (Tang
et al., 2008), without activating effector CD8+ T cells. Similarly,
pretreatment of mice with IL-2-anti-IL-2 complexes boosts
Treg cell numbers and ameliorates experimental allergic enceph-
alitis,myasthenia gravis, and graft rejection (Boyman andSprent,
2012). Beneficial effects of IL-2 have also been observed in
approximately half of patients with glucocorticoid refractory
chronic graft-versus-host disease, with expansion of Treg but
not conventional T cells (Koreth et al., 2011). Similarly, low-dose
IL-2 increased Treg cells in patients with autoimmune vasculitis
secondary to hepatitis C virus infection (Saadoun et al., 2011).
IL-2 and T Helper Cell Differentiation
CD4+ T cells can differentiate into multiple helper T cell popula-
tions upon antigen exposure, including Th1, Th2, Th9, Th17, and
Tfh cells (Crotty, 2011; Jabeen and Kaplan, 2012; Littman and
Rudensky, 2010; Paul and Zhu, 2010; Szabo et al., 2003)
(Figure 5). IL-12 drives the differentiation of Th1 cells, which
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produce IL-4, IL-5, and IL-13; the combination of IL-4 and
TGF-b drives differentiation of Th9 cells which produce IL-9;
IL-6 + TGF-b drives differentiation of Th17 cells, which produce
IL-17A, IL-17F, and IL-22; and IL-6 + IL-21 promotes the differ-
entiation of Tfh cells. These differentiation pathways are not
necessarily terminal, however, and subsets of Th cells can
acquire the ability to produce other Th cell-specific cytokine(s)
(O’Shea and Paul, 2010).
Th1 Cell Differentiation
Th1 cells mediate host defense to viruses and intracellular path-
ogens and contribute to the development of pathogenic inflam-
matory diseases based on their production of IFN-g. IL-12 via
STAT4 is essential for driving Th1 cell differentiation and inducing
T-bet, promoting the survival andproliferation of Th1 cells, a tran-
scriptionally permissive chromatin structure at the Ifng locus,
and enhanced IL-12Rb2 expression (Afkarian et al., 2002; Szabo
et al., 2003; Zhang and Boothby, 2006). IL-2 induces IFN-g, both
by inducing T cell proliferation (Bird et al., 1998) and via a STAT5-
dependent mechanism (Shi et al., 2008). Moreover, IL-2 via
STAT5 also rapidly induces IL-12Rb2 (Liao et al., 2011), aug-
menting responsiveness to IL-12. Retroviral expression of
IL-12Rb2 could restore diminished Th1 cell differentiation in
Il2/ T cells; thus, IL-2-induced IL-12Rb2 is critical for Th1 cell
differentiation. IL-2 also induces Tbx21, which encodes T-bet,
but T-bet alone could not restore Th1 cell differentiation (Liao
et al., 2011). An essential role for IL-2 in Th1 cell differentiation
in vivo has also been reported using Il27r/ mice. These mice
have elevated production of IL-2, and when infected with
T. gondii, they developed a lethal inflammatory disease associ-
ated with increased IFN-g that is diminished by IL-2 blockade
(Villarino et al., 2006).
Th2 Cell Differentiation
Th2 cells control humoral immunity to extracellular parasites and
mediate allergic inflammatory responses (Paul and Zhu, 2010).
In vitro Th2 differentiation requires the TCR-mediated activation
of naive CD4+ T cells in the presence of anti-IFN-g, IL-2, and IL-4,
with IL-2 promoting chromatin accessibility at the Il4 locus
(Cote-Sierra et al., 2004). TCR stimulation induces IL-4Ra
expression by an IL-2 and STAT5-dependent mechanism,
promoting cellular responsiveness to IL-4, and transduction of
Il4ra into Il2-deficient T cells can rescue Th2 cell differentiation
in the absence of IL-2 (Liao et al., 2008). IL-2-induced STAT5
binds throughout the Il4-Il13-Il5 Th2 cell-associated cytokine
locus cluster, at hypersensitive site 2 (HS2), HS3, and HS5, as
well as within the locus control region B and C elements in the
Rad50 gene (Liao et al., 2008). Thus, IL-2 via STAT5A and
STAT5B directly regulates IL-4Ra and IL-4 expression to
promote Th2 cell differentiation. Interestingly, other cytokines
that activate STAT5, including IL-7 and IL-15, also induce IL-
4Ra on T cells, suggesting that depending on the cellular
context, other cytokines can also prime CD4+ T cells for Th2
cell differentiation (Liao et al., 2008).
Th17 Cell Differentiation
Th17 cells produce IL-17A, IL-17F, and IL-22, which are impor-
tant for anti-bacterial and anti-fungal immunity, as well as inautoimmune diseases, including multiple sclerosis, psoriasis,
diabetes, rheumatoid arthritis, and Crohn’s disease (Littman
and Rudensky, 2010). Differentiation of Th17 cells can be
induced by IL-6 + TGF-b via an IL-6 to IL-23 to IL-21 cytokine
cascade (Littman andRudensky, 2010). IL-2 signaling decreases
Th17 cell generation, and when immunized, host mice receiving
adoptively transferred Il2/ CD4+ T cells generate more Th17
cells than did mice receiving wild-type cells (Laurence et al.,
2007). It has beenproposed that IL-2-activated STAT5 competes
with STAT3 for binding to sites in the Il17a locus, thus inhibiting
Il17a transcription (Yang et al., 2011), but direct STAT5 inhibition
of Il17a transcription has not been shown. IL-2 also inhibits
expression of both IL-6Ra and gp130, with increased expression
of these receptors in Il2/ T cells (Liao et al., 2011), and retroviral
transduction of Il6st, which encodes gp130, partially overcomes
IL-2-induced inhibition of IL-17A production (Liao et al., 2011).
Nevertheless, IL-2 partially inhibits IL-17A even when gp130 is
constitutively expressed, indicating that IL-2 also inhibits Th17
cell differentiation by a receptor-independent mechanism (Liao
et al., 2011). In this regard, IL-2 also induces expression of
Tbx21, which inhibits Th17 cell differentiation (Liao et al., 2011),
consistent with the ability of T-bet to interact with Runx1 and to
prevent association of Runx1 with RORgt, which is essential
for Th17 differentiation (Lazarevic et al., 2011). Interestingly, in
Th17 cells, Tbx21 retroviral transduction increases IFN-g
production, suggesting that IL-2 stimulation can promote
a Th17-to-Th1 cell shift in these cells (Liao et al., 2011). Although
IL-2 can inhibit Th17 cell differentiation, adults recently infected
with HIV-1 maintain peripheral Th17 cell numbers when treated
with IL-2 (Ndhlovu et al., 2010), and IL-2 can expand Th17 cells
once generated, which helps to explain benefits of anti-IL-2
receptor-based immunotherapy in uveitis and scleritis, where
Th17 cells are pathogenic (Amadi-Obi et al., 2007). Thus, IL-2
has complex actions on Th17 cells, inhibiting their differentiation
but promoting their expansion.
Tfh Cell Differentiation
Tfh cells reside in germinal centers and promote immunoglobulin
class switch and antibody affinity maturation by B cells (Crotty,
2011). Tfh cells are CD4+ T cells and both secrete and respond
to IL-21, augmenting their expression of ICOS, CXCR5, and
BCL6. IL-2 via STAT5 induces BLIMP1, which suppresses Tfh
differentiation and germinal center formation (Ballesteros-Tato
et al., 2012; Johnston et al., 2012); IL-2 also inhibits BCL6 in
Th1 cells, which suppresses a Tfh-like gene profile (Oestreich
et al., 2012).
IL-2 and Effector-Memory Cytolytic CD8+ T Cell
Differentiation
Besides its actions on Th cell populations, IL-2 drives develop-
ment of naive CD8+ T cells into effector and memory cytolytic
T-lymphocytes (CTL) upon antigen stimulation in the context of
infection or inflammation, with induction of IFN-g, perforin, and
granzymes (Pipkin et al., 2010). IL-2 increases expression of
the transcription factor Eomes, which together with STAT5 upre-
gulates Prf1 expression (Pipkin et al., 2010). IL-2 also potently
suppresses BCL6 (Pipkin et al., 2010) and IL-7Ra (Xue et al.,
2002). Resting CD8+ T cells express IL-2Rb and gc, so concen-
trations of IL-2 sufficient to titrate intermediate affinity receptorsImmunity 38, January 24, 2013 ª2013 Elsevier Inc. 19
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requires formation of STAT5 tetramers (Lin et al., 2012), as well
as the proliferation of activated CD8+ T cells that express high-
affinity IL-2 receptors.
In LCMV infection, in contrast toWT cells, Il2ra/CD8+ T cells
do not expand to secondary antigen exposure even though they
robustly respond to primary viral infection, indicating a critical
role for IL-2 in development of the memory response (Williams
et al., 2006). During infection, CD25 expression is initially high
but then becomes heterogeneous; cells that downregulate
CD25 early in infection receive a less prolonged or ‘‘intense’’
IL-2 signal, upregulate IL-7Ra and CD62L, and eventually
become long-lived memory cells, whereas cells expressing
higher numbers of CD25 molecules undergo more rapid prolifer-
ation, exhibit a terminally differentiated effector phenotype, and
are eliminated by apoptosis (Kalia et al., 2010; Williams et al.,
2006). A critical role for endogenous IL-2 production in the
antiviral response has also been demonstrated using Il2/
mice (Cousens et al., 1995). Moreover, autocrine production of
IL-2 by CD8+ T cells is important for the development of memory
CD8+ T cells in vivo (Feau et al., 2011). Overall, these studies
support the model that both the duration and strength of the
IL-2 signal is important, with contributions of IL-2 to the genera-
tion of effector cells as well as memory cell differentiation.
IL-2 and Adult T Cell Leukemia-Lymphoma (ATL)
Human T cell lymphotropic virus, type 1 (HTLV-1) is a retrovirus
that causes adult T cell leukemia-lymphoma (ATL) and tropical
spastic paraparesis-HTLV-1 associated myelopathy (TSP-
HAM). In the early phase of ATL, there is a period of autocrine
growth of leukemic CD4+ T cells, with expression of IL-2 and
functional IL-2 receptors, and anti-Tac mAb to human IL-2Ra
can decrease proliferation of these cells during this phase of
ATL (Waldmann et al., 2001). Over time, however, IL-2 produc-
tion is lost, although cell surface IL-2Ra expression persists,
and this later phase is associated with IL-2-independent growth.
Interestingly, ATL cells exhibit Treg cell-like suppressor activity
(Waldmann et al., 1984). In many patients, this later phase is
associated with a constitutively-activated JAK-STAT pathway
(Migone et al., 1995). Humanized anti-Tac (daclizumab or
Zenopax) (Figure 4) was approved by the FDA to prevent renal
allograft rejection but has also been used to treat patients with
ATL (Waldmann, 2007) and relapsing-remittingmultiple sclerosis
(Martin, 2012); whereas the antibody alonewas effective in a very
limited number of individuals, coupling the antibody to immuno-
toxin-linked mAbs or arming it with 90Y are approaches that have
been used to enhance effectiveness (Waldmann, 2007).
IL-2 as a Therapeutic Modality
IL-2 immunotherapy has been used for many years, with FDA
approval in 1992 for metastatic renal cell carcinoma and in
1998 for metastatic melanoma. IL-2 treatment can result in com-
plete remission of 5%–10% of patients with these diseases, with
lack of recurrence for as long as 25 years and potential cures of
70% of these individuals, with complete tumor regression
(Rosenberg, 2012). However, this represents only a small frac-
tion of the patients. Vaccination with a melanoma peptide
vaccine can significantly improve effectiveness (Schwartzen-
truber et al., 2011), and the addition of adoptive cell transfer20 Immunity 38, January 24, 2013 ª2013 Elsevier Inc.approaches have improved cure rates for metastatic melanoma
to between 20% and 40% (Rosenberg, 2012). Such treatment
involves the isolation of tumor infiltrating lymphocytes (TILs)
grown from a patient’s tumor and expansion of these autologous
TILs prior to their reintroduction (Rosenberg, 2012). A limitation
of IL-2 is its toxicity, including severe capillary leak syndrome
that can accompany such treatment. In mice, endothelial nitric
oxide synthase appears to play a critical role in the development
of IL-2-induced capillary leak syndrome (Samlowski et al., 2011).
Interestingly, although IL-2 is a potent T cell growth factor, in
animal models in which adoptive immunotherapy has been
performed, IL-2 is less effective as an anti-tumor agent than
IL-21, which inhibits expression of IL-2Ra on CD8+ T cells,
potentially decreasing the responsiveness of cells to IL-2
(Hinrichs et al., 2008). The decreased antitumor effect has
been potentially attributed to the more potent induction of
terminal effector CTL differentiation by IL-2, whereas IL-21-
treated CD8+ T cells persist for longer periods of time in vivo.
Recently, ‘‘super-IL-2’’ variants of IL-2 have been developed
that exhibit enhanced binding to IL-2Rb and do not require IL-
2Ra (Levin et al., 2012). As compared to wild-type IL-2, they
induce greater expansion of cytotoxic T cells but less expansion
of Treg cells, with reduced pulmonary edema in mice when
administered in vivo (Levin et al., 2012). Based on the crystal
structure, the mutations that result in the augmented function
are mainly in the core structure and stabilize IL-2, reducing the
flexibility of a helix in the IL-2Rb binding site and resulting in
a conformation that is normally achieved only in the presence
of IL-2Ra (Levin et al., 2012). Presumably for this reason, the
IL-2 superkine induces vigorous signaling and phosphorylation
in the absence IL-2Ra (Levin et al., 2012). More studies are
needed to determine whether this or another engineered IL-2
has therapeutic advantages over wild-type IL-2.
Inhibition of IL-2 Signaling as a Therapeutic Modality
In addition to dicluzamib, other modes of IL-2 inhibition are
possible. As noted above, IL-2 activates JAK1 and JAK3, with
JAK1 associating with IL-2Rb and JAK3 with gc (Russell et al.,
1994), and it was proposed that inhibitors of JAK3 would be
immunosuppressive (Russell et al., 1995). Two JAK inhibitors
are now available for clinical use. Ruxolitinib (Jakafi) inhibits
JAK1 > JAK2 (Harrison et al., 2012) and has been approved by
the FDA for treating myelofibrosis, with ongoing clinical trials
for primary polycythemia and primary thrombocythemia. Tofaci-
tinib (Changelian et al., 2003; Kremer et al., 2009), which inhibits
JAK3 > JAK1 and JAK2 and has also been approved for the treat-
ment of rheumatoid arthritis, based on successful clinical trials
(Kontzias et al., 2012), with ongoing Phase III clinical trials for
the treatment of psoriasis (Figure 4). Other JAK inhibitors are
being evaluated for use in rheumatoid arthritis and other diseases
as well. It is important to note that these agents inhibit not only
IL-2, but also other cytokines that utilized the inhibited JAK
kinases. Finally, IL-2 mutants with inhibitory activity as well as
structural-based medicinal chemistry approaches (Wilson and
Arkin, 2011) may also potentially yield useful inhibitors of IL-2.
Concluding Remarks and Perspective
As discussed herein, IL-2 mediates diverse pleiotropic actions,
promoting T cell proliferation, survival, cytolytic activity, NK cell
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inducing IL-12Rb2 and IL-4Ra but suppressing gp130 expres-
sion, IL-2 increases responsiveness to IL-12 and IL-4 to promote
Th1 and Th2 cell differentiation while inhibiting the IL-6 to IL-23 to
IL-21 cytokine cascade that drives Th17 cell differentiation,
and furthermore, its induction of IL-2Rb not only increases
responsiveness to IL-2 but also to IL-15, with potential impact
on CTL and NK activity. Thus, IL-2 does not by itself determine
the eventual differentiation but rather facilitates or inhibits
responsiveness to other cytokines, in part by promoting or inhib-
iting different cytokine cascades. Consistent with its potent
proliferative activity for T cells, IL-2 promotes the expansion of
multiple populations, including even Th17 cells whose differenti-
ation it inhibits. The amount of IL-2 produced, when and where
IL-2 receptors are expressed, the affinities (high- or interme-
diate-affinity) of these receptors, and the other cytokines present
in the cellular milieu, are critical in determining the biological
outcome orchestrated by IL-2 during an immune response.
Moreover, different populations of responding cells can poten-
tially compete for IL-2, and Treg cells expressing high affinity
IL-2Rs can efficiently compete for limited amount IL-2 with
effector cells that express intermediate affinity IL-2Rs (Busse
et al., 2010; Pandiyan et al., 2007). Furthermore, when IL-2
production by effector cells is abrogated during acute massive
inflammation in lethal T. gondii infection, there is a marked
decrease in Treg cell numbers and function that was reversed
by exogenous IL-2 (Oldenhove et al., 2009). Another complexity
is the possible competition among gc family cytokines. For
example, if one gc family cytokine is more abundant than others,
it might quantitatively recruit gc to its receptor, thereby effec-
tively sequestering gc and diminishing cellular responsiveness
to the other cytokines. Overall, we have tremendous knowledge
regarding how IL-2 and its receptor are regulated as well as
related to its structure, its signaling pathways, and its relation-
ship to the five other cytokines that share gc. These basic
research findings have led to the development of new
therapeutic approaches potentially applicable to a range of
diseases, either based on the administration of IL-2 or by using
antagonists of IL-2 production or signaling. How and when it is
desirable to modulate the IL-2 response is context-dependent.
For example, promoting effector activity may be a desired
response for treatment of cancer, whereas blocking effector
responses or augmenting Treg cell activity may be beneficial in
preventing autoimmunity or massive inflammatory responses,
as noted above related to T. gondii. Thus, directed manipulation
of the activities of this cytokine, which has major actions both
related to effector T cells and in tolerance, could have implica-
tions for controlling complex immune responses and for immu-
notherapy of a range of diseases. Moreover, future studies
directed toward comprehensively mapping the IL-2 signaling
network and further elucidating the molecular mechanisms of
IL-2 action could facilitate the development of better agonists
and more specific antagonists to efficiently modulate immune
responses.
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